Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency
- 11 March 2004
- journal article
- case report
- Published by Wiley in Haemophilia
- Vol. 10 (3) , 295-298
- https://doi.org/10.1111/j.1365-2516.2004.00885.x
Abstract
Summary. Use of recombinant factor VIIa (rFVIIa, NovoSeven®) in patients with congenital FVII deficiency has been reported for the prophylactic management of surgical bleeding and for the treatment of acute bleeding episodes. Because of its short half‐life, the use of rFVIIa on a regular prophylactic regimen has not been routinely adopted. In this report, we describe our successful experience with rFVIIa prophylaxis in preventing recurrent target joint bleeding in a severely FVII‐deficient adolescent.Keywords
This publication has 17 references indexed in Scilit:
- Home‐based factor infusion therapy and hospitalization for bleeding complications among males with haemophiliaHaemophilia, 2001
- Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiencyHaemophilia, 2000
- Use of Recombinant, Activated Factor VII in the Treatment of Congenital Factor VII DeficienciesVox Sanguinis, 1999
- Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitorsHaemophilia, 1999
- Clinical picture and treatment strategies in factor VII deficiencyHaemophilia, 1998
- Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiencyHaemophilia, 1997
- Use of recombinant factor VIIa in surgery in factor‐VII‐deficient patientsHaemophilia, 1997
- A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacsJournal of Internal Medicine, 1994
- Pharmacokinetics and pharmacodynamics of recombinant factor VIIaClinical Pharmacology & Therapeutics, 1994
- Factor VII deficiencyAmerican Journal of Hematology, 1981